Chibaudel et al.,(1313. Chibaudel B, Lacave R, Lefevre M, Soussan P, Antoine M, Périé S, et al. Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study. Cancer Med. 2015;4(5):721-31.) |
42 patients Mean age: 56 years Oropharyngeal carcinoma |
Cetuximab (IV) D1, 8 and 15 Cisplatin D1, 8 and 15 5-FU 750mg/m2 D1-5 |
G0 = 27 (65.8%) G1 = 5 (12.2%) G2 = 4 (9.8%) G3 = 5 (12.2%) G4 = 0 |
Bano et al.,(1414. Bano N, Najam R, Qazi F, Mateen A. Gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with different schedules of FOLFOX. Asian Pac J Cancer Prev. 2014;15(19):8089-93.) |
38 patients Mean age: 61 years Colorectal carcinoma Protocol 1 = 13 patients Protocol 2 = 12 patients Protocol 3 = 5 patients Protocol 4 = 8 patients |
Protocol 1 - FOLFOX 4 - Oxaliplatin 85mg/m2 (IV) D1 - 5-FU 400mg/m2 IV bolus + 600mg/m2 continuous D1 and 2 - Leucovorin 200mg/m2 D1 and 2 Protocol 2 - FOLFOX 6 - Oxaliplatin 100mg/m2 (IV) D1 - 5-FU 400mg/m2 IV bolus + 2,400mg/m2 continuous D1 and 2 - Leucovorin 400mg/m2 D1 and 2 Protocol 3 - mFOLFOX 6 - Oxaliplatin 100mg/m2 (IV) D1 - 5-FU 2,000mg/m2 continuous D1 and 2 - Leucovorin 100mg/m2 D1 and 2 Protocol 4 - FOLFOX 7 - Oxaliplatin 130mg/m2 (IV) D1 - 5-FU 2,400mg/m2 continuous D1 and 2 - Leucovorin 400mg/m2 D1 and 2 |
Protocol 1 - G0 = 24% G1 and 2= 65% G3 and 4 = 11%
Protocol 2 - G0 = 38% G1 and 2 = 56% G3 and 4 = 6%
Protocol 3 - G0 = 21% G1 and 2 = 79% G3 and 4 = 0
Protocol 4 - G0 = 7% G1 and 2 = 90% G3 and 4 = 3% |
Wang et al.,(1515. Wang HM, Hsu CL, Hsieh CH, Fan KH, Lin CY, Chang JT. Concurrent chemoradiotherapy using cisplatin, tegafur, and leucovorin for advanced squamous cell carcinoma of the hypopharynx and oropharynx. Biomed J. 2014;37(3):133-40.) |
65 patients Mean age: not informed Oropharyngeal and hypopharyngeal carcinoma |
Cisplatin 50mg/m2 (IV) D1 Tegafur 800mg (PO) D1-14 Leucovorin 60mg (PO) D1-14 |
G0 = 3.1% G1 = 1.5% G2 = 15.4% G3 = 73.8% G4 = 6.2% |
Aapro et al.,(1616. Aapro M, Andre F, Blackwell K, Clavo E, Jahanzeb M, Papazisis K, et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol. 2014;25(4):763-73. Review.) |
1. Renal carcinoma = 274 patients 2. Neuroendocrine tumors = 204 patients 3. Breast cancer = 482 patients Mean age: not informed |
Everolimus |
1. G1-G4 = 44% 2. G1-G4 = 64% 3. G1-G4 = 59% |
Tao et al.,(1717. Tao CJ, Liu X, Tang LL, Mao YP, Chen L, Li WF, et al. Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma. Chin J Cancer. 2013;32(10):525-32.) |
34 patients Mean age: 16 years Nasopharyngeal carcinoma |
Cisplatin 5-FU Radiation therapy |
G0 = 0 G1 = 10 (29.4%) G2 = 14 (41.2%) G3 = 9 (26.5%) G4 = 1 (2.9%) |
Lin et al.,(1818. Lin HX, Hua YJ, Chen QY, Luo DH, Sun R, Qiu F, et al. Randomized study of sinusoidal chronomodulated versus flat intermittent induction chemotherapy with cisplatin and 5-fluorouracil followed by traditional radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Chin J Cancer. 2013;32(9):502-11.) |
124 patients Mean age: 42 years Nasopharyngeal carcinoma |
3 cycles 5-FU 750mg/m2 D1-5 Radiation therapy |
1. G0 = 82 G1 and 2 = 42 G3 and 4 = 0 2. G0 = 58 G1 and 2 = 43 G3 and 4 = 14 3. G0 = 0 G1 and 2 = 64 G3 and 4 = 60 |
Iwata et al.,(1919. Iwata H, Fujii H, Masuda N, Mukai H, Nishimura Y, Katsura K, et al. Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study. Breast Cancer. 2015;22(2):192-200.) |
51 patients Mean age: 55 years Breast cancer |
Lapatinib 1,250mg qd Capecitabine 1,000mg/m2 bid |
G0 = 30 (59%) G1 = 21 (41%) G2 = 0 G3 = 0 G4 = 0 |
Palappallil et al.,(2020. Palappallil DS, Nair BL, Jayakumar KL, Puvathalil RT. Comparative study of the toxicity of 5-fluorouracil-adriamycin-cyclophosphamide versus adriamycincyclophosphamide followed by paclitaxel in carcinoma breast. Indian J Cancer. 2011;48(1):68-73.) |
1. 50 patients 2. 50 patients Mean age: 45 (20-70) years Breast cancer |
1. FAC 5-FU 500mg/m2 Doxorubicin 50mg/m2 Cyclophosphamide 500mg/m2 2. AC-P Doxorubicin 60mg/m2 Cyclophosphamide 600mg/m2 Paclitaxel 175mg/m2
|
1. G1-G4 = 45 (90%) 2. G1-G4 = 2 (4%) |
Baird et al.,(2121. Baird R, Biondo A, Chhaya V, McLachlan J, Karpathakis A, Rahman S, et al. Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. Br J Cancer. 2011;104(1):43-50.) |
1. 200 patients 2. 200 patients Mean age: 65 years Colorectal carcinoma |
1. CAPOX 2000 Capecitabine 2,000mg/m2 D1-14 Oxaliplatin 130mg/m2 D1 2. CAPOX 1.700 Capecitabine 1,700mg/m2 D1-14 Oxaliplatin 130mg/m2 D1 Cetuximab |
1. G1 = 22 (11%) G2 = 5 (2.5%) G3 = 0 (0%) G4 = 0 (0%) 2. G1 = 22 (11%) G2 = 5 (2.5%) G3 = 2 (1%) G4 = 0 (0%) |
Lee et al.,(2222. Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim TY, et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol. 2009;20(8):1402-7.) |
32 patients Mean age: 53 years Colorectal carcinoma |
Capecitabine 2,000mg/m2 D1-14 Cisplatin 60mg/m2 D1 |
G1-G2 = 4 (12.9%) G3-G4 = 1 (3.2%) |
Abromowitch et al.,(2323. Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J, Cairo MS; Children's Oncology Group. Shortened intensified multiagent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group. Br J Haematol. 2008;143(2):261-7.) |
1. 85 patients 2. 82 patients 3.1. 76 patients 3.2. 73 patients 3.3. 70 patients 3.4. 68 patients 3.5. 65 patients 3.6. 65 patients Mean age: 5.1 years Lymphoblastic leukemia |
1. Induction Vincristine 1.5mg/m2 D0, 7 and 14 Daunomycin 60mg/m2 D1 and 2 Cyclophosphamide 1,200mg/m2 D0 L-Asparaginase 2. Consolidation Vincristine 1.5mg/m2 D0 and 7 Cytarabine 2,000mg/m2 D0 and 1 Etoposide 200mg/m2 D0 and 1 Tioguanine 300mg/m2 D0-3 Methotrexate 1,000mg/m2 (IV) 3. Maintenance Cyclophosphamide 1,200mg/m2 D0 Tioguanine 300mg/m2 D0-3 Vincristine 15mg/m2 D14 and 21 Doxorubicin 30mg/m2 D14 Cyclophosphamide 1,200mg/m2 D0 Vincristine 15mg/m2 D28 Methotrexate 1,000mg/m2 (IV) |
1. Induction G1-G4 = 0 (0%) 2. Consolidation G1-G4 = 5 (6.1%) 3. Maintenance 3.1 G1-G4 = 3 (3.9%) 3.2 G1-G4 = 6 (8.2%) 3.3 G1-G4 = 2 (2.9%) 3.4 G1-G4 = 3 (4.4%) 3.5 G1-G4 = 1 (1.5%) 3.6 G1-G4 = 4 (6.2%) |
Shin et al.,(2424. Shin HJ, Chung JS, Lee JJ, Sohn SK, Choi YJ, Kim YK, et al. Treatment Outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis. J Korean Med Sci. 2008;23(3):439-44.) |
17 patients Mean age: 38 years Hemophagocytic lymphohistiocytosis |
CHOP Cyclophosphamide 750mg/m2 D1 Doxorubicin 50mg/m2 D1 Vincristine 1.4mg/m2 D1 Prednisone 40mg/m2 D1-5 |
G0 = 10 (58.84%) G1 = 2 (11.76%) G2 = 2 (11.76%) G3 = 3 (17.64%) G4 = 0 |
Blijlevens et al.,(2525. Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J, Niederwieser D, Rabitsch W, Roosaar A, Ruutu T, Schouten H, Stone R, Vokurka S, Quinn B, McCann S; European Blood and Marrow Transplantation Mucositis Advisory Group. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy-European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol. 2008;26(9):1519-25.) |
1. 109 patients with multiple myeloma Mean age: 56.8 years 2. 88 patients with non-Hodgkin's lymphoma Mean age: 50 years |
1. Melphalan 200mg/m2 2. BEAM Carmustine 300mg/m2 Etoposide 800mg/m2 Cytarabine 800-1,600mg/m2 Melphalan 140mg/m2
|
1. G0 = 10% G1-G2 = 44 % G3-G4 = 46% 2. G0 = 17% G1-G2 = 41% G3-G4 = 42% |
Fadda et al.,(2626. Fadda G, Campus G, Lugliè P. Risk factors for oral mucositis in paediatric oncology patients receiving alkylant chemotherapy. BMC Oral Health. 2006;6:13.) |
231 patients before HSCT Mean age: 7.6 years |
Alkylating agents 1. Melphalan 2. Busulfan 3. Others |
1. Melphalan G0 = 20 G1-G4 = 24 2. Busulfan G0 = 34 G1-G4 = 153 3. Others G0 = 42 G1-G4 = 64 |
Castagna et al.,(2727. Castagna L, Magagnoli M, Balzarotti M, Sarina B, Siracusano L, Nozza A, et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study. Am J Hematol. 2007;82(2):122-7.) |
1. 29 patients 2. 24 patients Mean age: 31 years HSCT Hodgkin's lymphoma |
1. Melphalan 200mg/m2 D1 2. BEAM Carmustine 300mg/m2 D1 Etoposide 800mg/m2 D1-4 Cytarabine 1,600mg/m2 D1-4 Melphalan 140mg/m2 D1 |
1. Melphalan - G3-G4 = 17 (60%) 2. BEAM - G3-G4 = 12 (50%) |
Oh et al.,(2828. Oh DY, Kim TY, Kwon JH, Lee JJ, Joh Y, Kim DW, et al. Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. Jpn J Clin Oncol. 2005;35(7):380-5.) |
43 patients Mean age: 55 years Gastric carcinoma |
Docetaxel 70mg/m2 5-FU 1200mg/m2 Cisplatin 40mg/m2
|
G1 = 1 (2.3%) G2 = 1 (2.3%) G3-G4 = 0 (0) |
Schmid et al.,(2929. Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol. 2005;23(3):432-40.) |
93 patients 1. 48 2. 45 Mean age: 1. 29 years 2. 25 years Breast cancer |
1. AT Doxorubicin 60mg/m2 Paclitaxel 200mg/m2 2. HDCT Mitoxantrone 45mg/m2 Cyclophosphamide 2,400mg/m2 Etoposide 2,500mg/m2
|
1. AT - G3-G4=4.6% 2. HDCT - G3-G4 = 26.3% |
Saini et al.,(3030. Saini A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer. 2003;88(12):1859-65.) |
716 patients Mean age: 63 years Colorectal carcinoma |
1. 5-FU 300mg/m2 IV continuous 2. 5-FU 425mg/m2 bolus D1-5 |
1. G3-G4 = 3.6% 2. G3-G4 = 19.6% |
Kremens et al.,(3131. Kremens B, Gruhn B, Klingebiel T, Hasan C, Laws HJ, Koscielniak E, et al. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant. 2002;30(12):893-8.) |
20 patients Mean age: 5.67 years Wilms tumor |
Melphalan 200mg/m2 D1-5 Etoposide Carboplatin |
G3-G4 = 10 (50%) |
Lacayo et al.,(3232. Lacayo NJ, Lum BL, Becton DL, Weinstein H, Ravindranath Y, Chang MN, et al. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia. 2002; 16(5):920-7.) |
38 patients 1. 15 2. 23 Mean age: not informed Acute myeloid leukemia |
1. DAT Daunomycin 45mg/m2 D1-3 Cytarabine 100mg/m2 D1-7 Tioguanine 100mg/m2 D1-7 2. DAT + high doses cytarabine DAT Cytarabine 1,000mg/m2 bid D1-7 |
1. DAT - G3-G4 = 2 (13%) 2. DAT + high doses cytarabine G3-G4 = 8 (35%) |
Leblond et al.,(3333. Leblond V, Lévy V, Maloisel F, Cazin B, Fermand JP, Harousseau JL, Remenieras L, Porcher R, Gardembas M, Marit G, Deconinck E, Desablens B, Guilhot F, Philippe G, Stamatoullas A, Guibon O; French Cooperative Group on Chronic Lymphocytic Leukemia and Macroglobulinemia. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood. 2001;98(9):2640-4.) |
1. 46 patients 2. 46 patients Mean age: 64 years Waldenström macroglobulinemia |
1. FAMP Fludarabine 25mg/m2 D1-5 2. CAP Cyclophosphamide 750mg/m2 D1 Doxorubicin 25mg/m2 D1 Prednisone 40mg/m2 D1-5 |
1. FAMP - G1-G4=0 2. CAP - G1-G4=10 |
Lissoni et al.,(3434. Lissoni A, Gabriele A, Gorga G, Tumolo S, Landoni F, Mangioni C, et al. Cisplatin, epirubicin and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol. 1997;8(10):969-72.) |
49 patients Mean age: 53.7 years Endometrial adenocarcinoma |
Epirubicin 70mg/m2 Paclitaxel 175mg/m2 Cisplatin 70mg/m2
|
G1 = 12 G2 = 0 G3 = 0 G4 = 0 |
Wang et al.,(3535. Wang WS, Tzeng CH, Chiou TJ, Liu JH, Hsieh RK, Yen CC, et al. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-hodgkin's lymphoma. Jpn J Clin Oncol. 1997;27(3):154-7. Review.) |
16 patients Mean age: 42.7 years Refractory non-Hodgkin's lymphoma |
Cytarabine 3,000mg/m2 bid D1-4 Mitoxantrone 6mg/m2 D1-5 |
G1 = 6 G2 = 2 G3 = 5 G4 = 1 |
Anderson et al.,(3636. Anderson H, Hopwood P, Prendiville J, Radford JA, Thatcher N, Ashcroft L. A randomized study of bolous vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. Br J Cancer. 1993;67(6):1385-90.) |
148 patients 1. Bolus = 78 2. Infusion = 70 Mean age: 61 years Small cell lung cancer |
Doxorubicin 35mg/m2 D1 Etoposide 100mg/m2 D1-5 Ifosfamide 5000mg/m2 D1 |
1. Bolus - G1-G4 = 24 (31%) 2. Infusion - G1-G4 = 37 (53%) |
Bishop et al.,(3737. Bishop JF, Lowenthal RM, Joshua D, Mattews JP, Todd D, Cobcroft R, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood. 1990;75(1):27-32.) |
274 patients Mean age: not informed Acute non-lymphocytic leukemia |
Daunorubicin 50mg/m2 D1-3 Etoposide 75mg/m2 D1-7 |
G3-G4 = 26% |
Clavel et al.,(3838. Clavel M, Cognetti F, Dodion P, Wildiers J, Rosso R, Rossi A, et al. Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck. Cancer. 1987;60(6):1173-7.) |
1. 93 patients 2. 92 patients Mean age: 57.5 years Head and neck cancer |
1. CABO Cisplatin 50mg/m2 D4 Methotrexate 40mg/m2 D1 and 15 Vincristine 2mg/m2 D1, 8 and 15 Bleomycin 10mg/m2 D1, 8 and 15 2. ABO Methotrexate 40mg/m2 D1, 8 and 15 Vincristine 2mg/m2 D1, 8 and 15 Bleomycin 10mg/m2 D1, 8 and 15 |
1. G3-G4 = 24% 2. G3-G4 = 31 |